RSV Is No Longer Just a Pediatric Problem: The Adult Vaccination Era Arrives

The shift is partly a success story. Pediatric RSV deaths have fallen meaningfully over time thanks to better supportive care and, more recently, monoclonal antibodies for infants. But the other half of the story is demographic and biological. Populations are older. Immune systems age. And RSV, it turns out, is a serious lower-respiratory pathogen in anyone whose lungs, heart, or immune defenses are already working harder than they used to.

What's new in 2025 is not the virus. It's the toolkit. Three adult RSV vaccines — RSVPreF3, RSVpreF, and the mRNA-based mRNA-1345 — have now been approved for adult use, the first time older adults have had any specific preventive option against a virus for which, the same review emphasizes, there is still no specific treatment in adults. That last point is the one worth sitting with. For RSV in a 75-year-old with COPD or heart failure, the medical playbook is oxygen, fluids, and time.

RSV is a leading cause of lower respiratory tract infections worldwide, and the review frames it bluntly as a major health threat especially for children and older adults. The under-5 burden has been studied for generations; the older-adult burden has been hiding in plain sight, often misclassified as influenza, pneumonia, or a vague "viral exacerbation" of an underlying condition. Better diagnostics have pulled it into focus.

The biology is unforgiving in older lungs. RSV inflames the small airways, and small airways in a 70-year-old don't recover the way they do in a toddler. Layer on common comorbidities — chronic obstructive pulmonary disease, congestive heart failure, diabetes, immune suppression from cancer therapy — and a virus most people would shrug off becomes a hospitalization, sometimes a fatal one. The review situates this within a broader pattern: as pediatric deaths fall, RSV appears increasingly significant for the elderly and adults with underlying health conditions.

The three approved adult vaccines take different technical routes to the same target: the RSV fusion protein in its pre-fusion shape, the configuration the virus uses to enter human cells. RSVPreF3 and RSVpreF are protein-based; mRNA-1345 uses messenger RNA, the same platform familiar from COVID-19 vaccines. All three are approved for adults, and the review's stated purpose is to summarize the safety and efficacy evidence behind them.

The honest framing is that this is a moderate-confidence moment. The evidence base is real and growing, the regulatory bar has been cleared in multiple jurisdictions, and the public-health rationale — a serious disease with no specific treatment and a clearly identified at-risk population — is straightforward. What remains less settled, and what readers should expect to see refined over the next several seasons, is the durability of protection, the optimal interval between doses, and how the three vaccines compare head-to-head in the populations that need them most.

A predictable side effect of any new adult vaccine category is a wave of adjacent marketing: immune-boosting lozenges, "lung support" botanicals, megadose vitamin stacks pitched at exactly the demographic the vaccines target. None of that is what the evidence in this review is about. The cited paper is a synthesis of epidemiology and vaccine data, not a verdict on supplements, and nothing in it suggests an over-the-counter substitute for a vaccine against a virus with no specific treatment.

The cleaner read is that RSV has joined influenza and pneumococcal disease on the short list of respiratory threats with both a defined at-risk adult population and a specific preventive tool. Whether any individual reader is in that population — and which of the three vaccines, if any, fits — is a clinical conversation, not a checkout-aisle one.

The RSV story is a small case study in something larger: the diseases of healthy aging are not the diseases of midlife with a few extra wrinkles. They are, often, different diseases — or familiar diseases behaving differently because the host has changed. The same review notes the situation in low- and middle-income countries, where aging populations and constrained vaccine access will shape who actually benefits from this new category over the next decade.

For now, the practical takeaway is narrow and defensible. RSV is a meaningful adult risk, especially after 70 and especially with chronic illness. Three vaccines exist where none did a few years ago. The evidence supporting them is moderate and improving. And the right next step, for anyone seeing themselves in this picture, is a conversation with a clinician — not a new bottle on the shelf.